Liaoning Cheng Da (600739.SH) subsidiary plans to contribute US$5 million to subscribe for private fund shares.

Liaoning Cheng Da (600739.SH) announced that, in order to better implement the company's strategic planning and promptly seize investment opportunities in the biopharmaceutical field, its wholly-owned subsidiary Chengda Steel Hong Kong plans to contribute US$5 million of its own funds as a limited partner to subscribe for fund shares of Likon Venture Fund II Limited Partnership (Cayman) (the "Target Fund"). The Target Fund has a total fundraising target of no less than US$60 million, with the first closing target at no less than US$35 million. The general partner is Likon Fortune II Ltd. (Cayman), and the fund management company is Elikon Advisors Inc. The Target Fund's main business is equity investment in early-stage companies in the biopharmaceutical and healthcare industries, while also covering equity investment in growth-stage companies. The aforementioned investment targets include, but are not limited to, companies in innovative drugs and their upstream and downstream industries, medical devices, medical diagnostic equipment and reagents, and related service sectors. After the completion of this investment, the Target Fund will not be included in the scope of the company's consolidated financial statements.